Mylotarg Injection (4.5mg), which contains the active ingredient Gemtuzumab ozogamicin, is a targeted therapy used primarily in the treatment of acute myeloid leukemia (AML), particularly in patients with specific genetic markers. This medication is a conjugate of a humanized monoclonal antibody and a cytotoxic agent, designed to deliver the chemotherapy drug directly to cancer cells, thereby minimizing damage to healthy cells. Mylotarg works by binding to CD33, a protein commonly found on the surface of leukemia cells, facilitating the internalization of the cytotoxic agent and leading to cell death. The injection is typically administered in a clinical setting under the supervision of healthcare professionals, ensuring that patients receive the appropriate dosage and monitoring for any adverse effects. Mylotarg is an important option for patients with relapsed or refractory AML, offering a targeted approach to treatment that can improve outcomes and quality of life.